drugset / Trial / NCT03802786
Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, single-centre, open-label, parallel-group study in subjects with moderate hepatic impairment and subjects with normal hepatic function. Child-Pugh (CP) scoring will be used to determine hepatic impairment.
Timeline
- Start
- 2018-11-06
- Primary completion
- 2019-07-03
- Completion
- 2019-07-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imeglimin | Small molecule | — | — |
Indications
No indication recorded.